Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FULC NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$3.70$6.16$2.83▼$15.74$246.54M2.934.58 million shs6.10 million shsSPRBSpruce Biosciences$52.36$54.95$4.77▼$240.00$144.11M3.1156,032 shs171,016 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics0.00%+7.25%-41.73%-45.35%-41.82%SPRBSpruce Biosciences0.00%+0.91%+1.65%-10.34%+870.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$3.70$6.16$2.83▼$15.74$246.54M2.934.58 million shs6.10 million shsSPRBSpruce Biosciences$52.36$54.95$4.77▼$240.00$144.11M3.1156,032 shs171,016 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics0.00%+7.25%-41.73%-45.35%-41.82%SPRBSpruce Biosciences0.00%+0.91%+1.65%-10.34%+870.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFULCFulcrum Therapeutics 1.75Reduce$8.20121.62% UpsideSPRBSpruce Biosciences 2.60Moderate Buy$163.00211.31% UpsideCurrent Analyst Ratings BreakdownLatest SPRB and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026SPRBSpruce Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$123.006/16/2026SPRBSpruce Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$123.006/9/2026SPRBSpruce Biosciences JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$135.006/5/2026SPRBSpruce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/3/2026FULCFulcrum Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight6/2/2026FULCFulcrum Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeUnderperform ➝ Underweight6/2/2026FULCFulcrum Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.006/2/2026FULCFulcrum Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$4.006/2/2026FULCFulcrum Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$3.006/2/2026FULCFulcrum Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026FULCFulcrum Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$4.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFULCFulcrum Therapeutics$80M3.08N/AN/A$6.45 per share0.57SPRBSpruce BiosciencesN/AN/AN/AN/A$39.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)SPRBSpruce Biosciences-$38.97M-$36.60N/AN/AN/AN/A-155.40%-101.67%8/13/2026 (Estimated)Latest SPRB and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SPRBSpruce Biosciences-$7.9340-$8.94-$1.0060-$8.94N/AN/A4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFULCFulcrum TherapeuticsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFULCFulcrum TherapeuticsN/A34.3334.33SPRBSpruce Biosciences0.164.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFULCFulcrum Therapeutics89.83%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipFULCFulcrum Therapeutics7.30%SPRBSpruce Biosciences4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFULCFulcrum Therapeutics10066.63 million61.77 millionOptionableSPRBSpruce Biosciences202.75 million2.63 millionOptionableSPRB and FULC HeadlinesRecent News About These CompaniesSpruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate ControllerJune 15, 2026 | finance.yahoo.comSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumJune 8, 2026 | businesswire.comSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumMay 28, 2026 | businesswire.comSpruce Biosciences to Participate in Upcoming Conferences in JuneMay 27, 2026 | businesswire.comSpruce Biosciences Stockholders Approve Directors and Annual Say-on-PayMay 26, 2026 | tipranks.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | businesswire.comSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President ...May 4, 2026 | bakersfield.comBCraig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendationApril 28, 2026 | msn.comWhy is Spruce Biosciences stock sinking Tuesday?April 21, 2026 | msn.comSpruce Biosciences prices $60M public offering at $50.00 per shareApril 21, 2026 | msn.comSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | businesswire.comSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | finance.yahoo.comWall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeApril 3, 2026 | zacks.comDoes Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?March 18, 2026 | zacks.comSpruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net LossMarch 17, 2026 | insidermonkey.comSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerMarch 9, 2026 | pharmiweb.comPSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesMarch 9, 2026 | businesswire.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | insidermonkey.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | msn.comSpruce Biosciences to Present at Upcoming Investor Conferences in MarchMarch 2, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRB and FULC Company DescriptionsFulcrum Therapeutics NASDAQ:FULC$3.70 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.70 -0.01 (-0.14%) As of 06/18/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Spruce Biosciences NASDAQ:SPRB$52.36 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$50.24 -2.12 (-4.04%) As of 06/18/2026 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
